# Mycophenolate plus methylprednisolone versus methy moderate-to-severe Graves' orbitopathy (MINGO): a ran multicentre trial

Lancet Diabetes and Endocrinology,the

6, 287-298

DOI: 10.1016/s2213-8587(18)30020-2

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Graves' orbitopathy: the ongoing search for new treatment strategies. Lancet Diabetes and Endocrinology,the, 2018, 6, 261-263. | 5.5 | 4 |
| 2 | Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 363-395. | 2.6 | 26 |
| 3 | Corticosteroids for Gravesâ€™ Ophthalmopathy: Systematic Review and Meta-Analysis. BioMed Research International, 2018, 2018, 1-9. | 0.9 | 19 |
| 4 | Combined immunosuppressants and less steroids in active gravesâ€™ orbitopathy?. Clinical Endocrinology, 2018, 90, 525-527. | 1.2 | 3 |
| 5 | Current and Future Treatments for Gravesâ€™ Disease and Gravesâ€™ Ophthalmopathy. Hormone and Metabolic Research, 2018, 50, 871-886. | 0.7 | 27 |
| 6 | Step-down steroid-sparing therapy in active thyroid eyeÂdisease. Nature Reviews Endocrinology, 2018, 14, 634-635. | 4.3 | 4 |
| 7 | Gravesâ€™ orbitopathy: Diagnosis and treatment. Annales D'Endocrinologie, 2018, 79, 656-664. | 0.6 | 19 |
| 8 | Thyroid Autoimmunity. , 2018, , 636-650. | | 0 |
| 9 | Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annual Review of Pharmacology and Toxicology, 2019, 59, 129-148. | 4.2 | 25 |
| 10 | Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Gravesâ€™ disease and Gravesâ€™ orbitopathy. Journal of Endocrinological Investigation, 2019, 42, 471-480. | 1.8 | 37 |
| 11 | Current and Emerging Treatment Strategies for Gravesâ€™ Orbitopathy. Drugs, 2019, 79, 109-124. | 4.9 | 56 |
| 12 | Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocrine Reviews, 2019, 40, 236-267. | 8.9 | 117 |
| 13 | Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Gravesâ€™ orbitopathy?. Journal of Endocrinological Investigation, 2019, 42, 351-352. | 1.8 | 6 |
| 14 | Basic Fibroblast Growth Factor Induces Adipogenesis in Orbital Fibroblasts: Implications for the Pathogenesis of Graves' Orbitopathy. Thyroid, 2019, 29, 395-404. | 2.4 | 12 |
| 15 | Immunological Aspects of Gravesâ€™ Ophthalmopathy. BioMed Research International, 2019, 2019, 1-12. | 0.9 | 63 |
| 16 | Immunotherapies for thyroid eye disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 250-255. | 1.2 | 18 |
| 17 | Update on the clinical assessment and management of thyroid eye disease. Current Opinion in Ophthalmology, 2019, 30, 401-406. | 1.3 | 23 |
| 18 | <p>Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1305-1318. | 0.9 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Treatment strategies for Gravesâ€™ ophthalmopathy: a network meta-analysis. British Journal of Ophthalmology, 2020, 104, 551-556. | 2.1 | 12 |
| 20 | Orbital diseases mimicking gravesâ€™ orbitopathy: a long-standing challenge in differential diagnosis. Journal of Endocrinological Investigation, 2020, 43, 401-411. | 1.8 | 39 |
| 21 | Thyroid eye disease: current and potential medical management. International Ophthalmology, 2020, 40, 1035-1048. | 0.6 | 8 |
| 22 | New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nature Reviews Endocrinology, 2020, 16, 104-116. | 4.3 | 155 |
| 23 | A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye, 2020, 34, 1662-1671. | 1.1 | 4 |
| 24 | Systemic safety analysis of mycophenolate in Gravesâ€™ orbitopathy. Journal of Endocrinological Investigation, 2020, 43, 767-777. | 1.8 | 22 |
| 25 | Medical and surgical treatment of thyroid eye disease. Internal Medicine Journal, 2022, 52, 14-20. | 0.5 | 7 |
| 26 | Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Gravesâ€™ Orbitopathy. European Thyroid Journal, 2020, 9, 3-16. | 1.2 | 23 |
| 27 | Advances in steroid sparing medical management of active thyroid eye disease. Seminars in Ophthalmology, 2020, 35, 216-223. | 0.8 | 1 |
| 28 | Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. European Thyroid Journal, 2020, 9, 31-39. | 1.2 | 5 |
| 29 | Teprotumumab: a disease modifying treatment for gravesâ€™ orbitopathy. Thyroid Research, 2020, 13, 12. | 0.7 | 8 |
| 30 | Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101383. | 2.2 | 10 |
| 31 | Teprotumumab for the treatment of thyroid eye disease. Expert Review of Clinical Immunology, 2020, 16, 739-743. | 1.3 | 3 |
| 33 | Management of Graves Thyroidal and Extrathyroidal Disease: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3704-3720. | 1.8 | 107 |
| 34 | Novel Approaches for Immunosuppression in Gravesâ€™ Hyperthyroidism and Associated Orbitopathy. European Thyroid Journal, 2020, 9, 17-30. | 1.2 | 18 |
| 35 | Glucocorticoids in Gravesâ€™ orbitopathy: mechanisms of action and clinical application. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882095833. | 1.4 | 12 |
| 36 | Antioxidant Therapy in Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2020, 11, 608733. | 1.5 | 8 |
| 37 | Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye, 2021, 35, 2607-2612. | 1.1 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Expert Opinion on Investigational Drugs, 2020, 29, 645-649. | 1.9 | 13 |
| 39 | Gravesâ€™ disease. Nature Reviews Disease Primers, 2020, 6, 52. | 18.1 | 199 |
| 41 | Low signal intensities of MRI T1 mapping predict refractory diplopia in Gravesâ€™ ophthalmopathy. Clinical Endocrinology, 2020, 92, 536-544. | 1.2 | 15 |
| 42 | Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factorâ€“I Receptor Inhibition. Journal of Neuro-Ophthalmology, 2020, 40, 74-83. | 0.4 | 5 |
| 43 | Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy. Frontiers in Endocrinology, 2019, 10, 933. | 1.5 | 27 |
| 44 | Thyrotropin receptor antibodies and Gravesâ€™ orbitopathy. Journal of Endocrinological Investigation, 2021, 44, 703-712. | 1.8 | 33 |
| 45 | Tratamiento de la oftalmopatÃa de Graves. Medicina ClÃnica, 2021, 156, 180-186. | 0.3 | 8 |
| 46 | Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. Thyroid, 2021, 31, 280-287. | 2.4 | 5 |
| 47 | A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Gravesâ€™ orbitopathy. Cellular and Molecular Immunology, 2021, 18, 735-745. | 4.8 | 37 |
| 48 | Glucocorticoids for Thyroid Eye Disease. International Ophthalmology Clinics, 2021, 61, 63-78. | 0.3 | 3 |
| 49 | Updates on the understanding and management of thyroid eye disease. Therapeutic Advances in Ophthalmology, 2021, 13, 251584142110277. | 0.8 | 19 |
| 50 | Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1325-1332. | 1.8 | 33 |
| 51 | Treatment of Gravesâ€™ ophthalmopathy. Medicina ClÃnica (English Edition), 2021, 156, 180-186. | 0.1 | 1 |
| 52 | Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2020, 11, 629925. | 1.5 | 22 |
| 53 | Thyroid Eye Disease: Navigating the New Treatment Landscape. Journal of the Endocrine Society, 2021, 5, bvab034. | 0.1 | 14 |
| 54 | Multidisciplinary approach to orbital decompression. A review. Acta Otorhinolaryngologica Italica, 2021, 41, S90-S101. | 0.7 | 6 |
| 55 | Graves' orbitopathy: a multidisciplinary approach. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 157-171. | 0.4 | 4 |
| 56 | Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy. Hormone and Metabolic Research, 2021, 53, 211-218. | 0.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 57 | Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease. Clinical Ophthalmology, 2021, Volume 15, 1921-1932. | 0.9 | 16 |
| 58 | Influence of 4â€week or 12â€week glucocorticoid treatment on metabolic changes in patients with active moderateâ€toâ€severe thyroidâ€associated ophthalmopathy. Clinical and Translational Science, 2021, 14, 1734-1746. | 1.5 | 3 |
| 60 | Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 360-372. | 5.5 | 91 |
| 61 | Recent advances in thyroid eye disease: An overview. IP International Journal of Ocular Oncology and Oculoplasty, 2021, 7, 117-130. | 0.0 | 2 |
| 62 | A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease. Ophthalmology, 2021, 128, 1125-1128. | 2.5 | 8 |
| 63 | A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Gravesâ€™ disease mouse model. Journal of Autoimmunity, 2021, 122, 102666. | 3.0 | 11 |
| 64 | 2021 update on thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 2022, 45, 235-259. | 1.8 | 44 |
| 65 | GravesÊ¼ Orbitopathy: Current Concepts for Medical Treatment. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 24-32. | 0.3 | 5 |
| 66 | Medical treatment in thyroid eye disease in 2020. British Journal of Ophthalmology, 2021, 105, 299-305. | 2.1 | 20 |
| 67 | Oxidative Stress in Graves Disease and Graves Orbitopathy. European Thyroid Journal, 2020, 9, 40-50. | 1.2 | 22 |
| 68 | Current Knowledge on Gravesâ€™ Orbitopathy. Journal of Clinical Medicine, 2021, 10, 16. | 1.0 | 26 |
| 69 | Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development. Taiwan Journal of Ophthalmology, 2020, 10, 174. | 0.3 | 8 |
| 70 | Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in anIn VitroModel of Graves' Orbitopathy. Thyroid, 2022, 32, 294-305. | 2.4 | 7 |
| 72 | Role of the mononuclear cell infiltrate in Gravesâ€™ orbitopathy (GO): results of a large cohort study. Journal of Endocrinological Investigation, 2022, 45, 563-572. | 1.8 | 9 |
| 74 | Management of thyroid diseases during pandemic: A narrative review. Thyroid Research and Practice, 2020, 17, 62. | 0.2 | 1 |
| 78 | Gravesâ€™ Orbitopathy. Encyclopedia of Pathology, 2022, , 1-6. | 0.0 | 0 |
| 79 | Gravesâ€™ Orbitopathy and Dermopathy. , 2022, , 506-518. | | 0 |
| 81 | Pathophysiology of thyroid-associated orbitopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101620. | 2.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 82 | Mycophenolate Mofetil (CellCeptÂ®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy. Frontiers in Medicine, 2022, 9, 788228. | 1.2 | 5 |
| 83 | Orbitopathie basedowienne. , 2022, , 160-179. | | 0 |
| 84 | Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease. JAMA Ophthalmology, 2022, 140, 328. | 1.4 | 29 |
| 85 | Comparative effectiveness of different treatment modalities for active, moderateâ€toâ€severe Graves' orbitopathy: a systematic review and network metaâ€analysis. Acta Ophthalmologica, 2022, 100, . | 0.6 | 3 |
| 86 | The Role of the Microbiota in Gravesâ€™ Disease and Gravesâ€™ Orbitopathy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 739707. | 1.8 | 22 |
| 87 | Drug safety in thyroid eye disease â€“ a systematic review. Expert Opinion on Drug Safety, 2022, , . | 1.0 | 1 |
| 88 | 2022ÂUpdate on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinology and Metabolism Clinics of North America, 2022, 51, 287-304. | 1.2 | 23 |
| 89 | Current concepts regarding Gravesâ€™ orbitopathy. Journal of Internal Medicine, 2022, 292, 692-716. | 2.7 | 37 |
| 90 | Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy. Current Neurology and Neuroscience Reports, 0, , . | 2.0 | 1 |
| 91 | Letter to the editor regarding Bartalena et al. 2022. Journal of Endocrinological Investigation, 0, , . | 1.8 | 1 |
| 92 | Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. Indian Journal of Ophthalmology, 2022, 70, 2335. | 0.5 | 6 |
| 93 | Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy. European Thyroid Journal, 2022, , . | 1.2 | 1 |
| 94 | Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Gravesâ€™ orbitopathy: a meta-analysis. Bioengineered, 2022, 13, 14719-14729. | 1.4 | 1 |
| 95 | Future Projections in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S47-S56. | 1.8 | 16 |
| 96 | Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S36-S46. | 1.8 | 7 |
| 97 | Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S13-S26. | 1.8 | 5 |
| 98 | Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. International Ophthalmology, 2023, 43, 1437-1449. | 0.6 | 1 |
| 99 | Gravesâ€™ Orbitopathy. Encyclopedia of Pathology, 2022, , 343-349. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 100 | Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid, 2022, 32, 1439-1470. | 2.4 | 36 |
| 101 | Role of Peripheral Regulatory T Lymphocytes in Patients with Thyroid Associated Ophthalmopathy During Systemic Glucocorticoid Treatment: A Prospective Observational Study. Current Medical Science, 0, , . | 0.7 | 0 |
| 102 | Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. European Thyroid Journal, 2022, 11, . | 1.2 | 19 |
| 103 | Rapamycin improves Gravesâ€™ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight, 2023, 8, . | 2.3 | 8 |
| 104 | Presentation of Gravesâ€™ orbitopathy within European Group On Gravesâ€™ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). British Journal of Ophthalmology, 2024, 108, 294-300. | 2.1 | 8 |
| 105 | Dysthyroid optic neuropathy: emerging treatment strategies. Journal of Endocrinological Investigation, 2023, 46, 1305-1316. | 1.8 | 5 |
| 106 | Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , . | 1.0 | 0 |
| 108 | Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients. Frontiers in Endocrinology, 0, 14, . | 1.5 | 1 |
| 109 | Medical Management of Thyroid Eye Disease. International Ophthalmology Clinics, 2023, 63, 81-89. | 0.3 | 0 |
| 110 | Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial. Journal of Clinical Endocrinology and Metabolism, 0, , . | 1.8 | 2 |
| 111 | Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease. American Journal of Ophthalmology, 2023, 252, 94-100. | 1.7 | 1 |
| 124 | Medical Management of Gravesâ€™ Orbitopathy. , 2023, , 287-293. | | 0 |
| 125 | Diagnosis of Gravesâ€™ Orbitopathy. , 2023, , 271-277. | | 0 |
| 126 | Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduction and Targeted Therapy, 2024, 9, . | 7.1 | 2 |